MiroBio raises $97 million in Series B financing

MiroBio, which is developing checkpoint agonists to treat autoimmune diseases, today announced the completion of a $97million (£80 million) Series B financing led by Medicxi with participation from new investors, OrbiMed and Monograph Capital and existing Series A investors, Oxford Science Enterprises, Samsara BioCapital, SR One and Advent Life Sciences.

MiroBio is a private biotechnology company formed last year out of the UK’s Oxford University and backed by a strong group of international investors.

The funds will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases. MB272 and MB151 are differentiated, precision-engineered checkpoint receptor agonists for BTLA (B- and T-Lymphocyte Attenuator) & PD-1 (Programmed cell Death protein 1) respectively, offering transformative therapeutic potential for patients. Proceeds will also be used to advance MiroBio’s pre-clinical pipeline and further develop the company’s proprietary I-ReSToRE discovery platform.

Following the fundraising Nick Williams of Medicxi and Erez Chimovits of OrbiMed will join MiroBio’s board of directors.